Why launch and portfolio strategy matter in MedTech
The global regulatory environment for medical devices is evolving rapidly, with increasing emphasis on continuous post-market evidence generation.
Under frameworks such as EU MDR / IVDR and FDA post-market requirements, manufacturers must demonstrate:
-
Ongoing safety and performance
-
Real-world clinical benefit
-
Continuous risk monitoring
-
Active post-market surveillance
Post-market evidence becomes critical when:
Preparing or updating regulatory submissions
Supporting recertification and audits
Expanding labels or indications
Monitoring real-world safety and performance
Strengthening market access and reimbursement dossiers
Without structured post-market research, manufacturers risk regulatory delays, weak clinical credibility, and limited evidence for lifecycle decisions.
Where post-market evidence fits in the MedTech lifecycle
Post-market evidence plays a critical role across multiple stages of the product lifecycle. It typically follows launch and market access and feeds directly into regulatory, clinical, and commercial strategy, ensuring decisions are grounded in real-world performance.
- Regulatory maintenance and recertification
- Post-launch clinical validation
- Market access and reimbursement support
- Product optimisation and iteration
- Portfolio and lifecycle strategy
A practical evidence base for regulation and growth
Our work delivers a structured, reusable evidence base that regulatory, clinical, and commercial teams can rely on over time. Outputs are designed to support regulatory submissions, clinical publications, internal decision-making, and external stakeholder communication, always grounded in real-world data.
Case Studies
Explore our case studies focusing on Post-Market Medical Device Surveys
Evidence to discover how we have supported our clients to succeed in the past.
